Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bennett, R. G.
Right arrow Articles by Duckworth, W. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bennett, R. G.
Right arrow Articles by Duckworth, W. C.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes, Vol 46, Issue 2 197-203, Copyright © 1997 by American Diabetes Association


ARTICLES

Characterization of the insulin inhibition of the peptidolytic activities of the insulin-degrading enzyme-proteasome complex

RG Bennett, FG Hamel and WC Duckworth
Department of Biochemistry and Molecular Biology, Veterans Affairs Medical Center, University of Nebraska Medical Center, Omaha 68198-3020, USA.

Insulin-degrading enzyme (IDE) is a component of a cytosolic complex that includes multicatalytic proteinase (MCP), the major cytoplasmic proteolytic activity. Insulin, the primary substrate for IDE, inhibits the proteolytic activity of the IDE-MCP complex but not of purified MCP. This provides a regulatory role for IDE in cellular proteolysis and a potential mechanism for intracellular insulin action. To examine the specificity and to explore the mechanisms for the IDE-MCP interaction, we studied the functional interaction of a variety of peptides with the complex. Atrial natriuretic peptide (ANP), relaxin, glucagon, proinsulin, and insulin-like growth factor II (IGF-II) bind to and are degraded by IDE. These peptides have significant inhibitory effects on the chymotrypsin-like and trypsin-like MCP catalytic activities but not the peptidyl-glutamyl hydrolyzing activity. A panel of peptides that are not ligands of IDE had no effect. To explore the potential mechanism for the IDE control of MCP activity, dose response curves for insulin-like growth factor I (IGF-I) and IGF-II effects on MCP chymotrypsin-like activity were determined. IGF-II, which (similar to insulin) is a good substrate for IDE, had a substantial inhibitory effect, whereas IGF-I, which is bound but poorly degraded, had little inhibitory activity on MCP. Proinsulin, another ligand of IDE that is tightly bound but poorly degraded, had a partial effect on MCP activity, but inhibited the full insulin effect. These data suggest a requirement for both the binding and degradation of IDE ligands for the full inhibition of MCP. Insulin-sized degradation products, substrates of IDE, also inhibited MCP activity. Further examination of the insulin effect on MCP included kinetic studies. Insulin produced a noncompetitive inhibition of both the chymotrypsin-like and trypsin-like activities of MCP. These data suggest that the insulin-IDE effect on MCP is due to conformational changes in the IDE-MCP complex and provide an intracellular mechanism of action for insulin.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Exp. Biol. Med.Home page
M. del Carmen Camberos and J. C. Cresto
Insulin-Degrading Enzyme Hydrolyzes ATP
Experimental Biology and Medicine, February 1, 2007; 232(2): 281 - 292.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
F. G. Hamel, J. L. Upward, and R. G. Bennett
In Vitro Inhibition of Insulin-Degrading Enzyme by Long-Chain Fatty Acids and Their Coenzyme A Thioesters
Endocrinology, June 1, 2003; 144(6): 2404 - 2408.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
D. G. Cook, J. B. Leverenz, P. J. McMillan, J. J. Kulstad, S. Ericksen, R. A. Roth, G. D. Schellenberg, L.-W. Jin, K. S. Kovacina, and S. Craft
Reduced Hippocampal Insulin-Degrading Enzyme in Late-Onset Alzheimer's Disease Is Associated with the Apolipoprotein E-{epsilon}4 Allele
Am. J. Pathol., January 1, 2003; 162(1): 313 - 319.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
F. G. Hamel, R. G. Bennett, J. L. Upward, and W. C. Duckworth
Insulin Inhibits Peroxisomal Fatty Acid Oxidation in Isolated Rat Hepatocytes
Endocrinology, June 1, 2001; 142(6): 2702 - 2706.
[Abstract] [Full Text] [PDF]


Home page
GeneticsHome page
J. Leips and T. F. C. Mackay
Quantitative Trait Loci for Life Span in Drosophila melanogaster: Interactions With Genetic Background and Larval Density
Genetics, August 1, 2000; 155(4): 1773 - 1788.
[Abstract] [Full Text]


Home page
EndocrinologyHome page
R. G. Bennett, F. G. Hamel, and W. C. Duckworth
Insulin Inhibits the Ubiquitin-Dependent Degrading Activity of the 26S Proteasome
Endocrinology, July 1, 2000; 141(7): 2508 - 2517.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
W. C. Duckworth, R. G. Bennett, and F. G. Hamel
Insulin Degradation: Progress and Potential
Endocr. Rev., October 1, 1998; 19(5): 608 - 624.
[Abstract] [Full Text]


Home page
EndocrinologyHome page
F. G. Hamel, R. G. Bennett, and W. C. Duckworth
Regulation of Multicatalytic Enzyme Activity by Insulin and the Insulin-Degrading Enzyme
Endocrinology, October 1, 1998; 139(10): 4061 - 4066.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Fawcett, F. G. Hamel, R. G. Bennett, Z. Vajo, and W. C. Duckworth
Insulin and Analogue Effects on Protein Degradation in Different Cell Types. DISSOCIATION BETWEEN BINDING AND ACTIVITY
J. Biol. Chem., April 6, 2001; 276(15): 11552 - 11558.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1997 by the American Diabetes Association.